|
|
|
|
|
|
|
|
|
|
PARP Inhibitors Advance in Ovarian Cancer
With
olaparib approved and niraparib and rucaparib advancing through
clinical development, PARP inhibition is becoming a valuable option in
the ovarian cancer armamentarium.
In a discussion at the 2016 CFS,™ Michael Birrer, MD, PhD, director of Medical Gynecologic Oncology at Massachusetts General Hospital, said he anticipates that the FDA will approve niraparib and rucaparib in ovarian cancer in the next 6 months to a year.
The focus now, according to Birrer, is on optimizing the use of these treatments. “We need to find the best patient population to treat and we need to define whether we use these drugs in maintenance treatment, or early or late [in sequencing].” - See more at: http://www.targetedonc.com/conference/cfs-2016/parp-inhibitors-advance-in-ovarian-cancer#sthash.FQHTlMVQ.dpuf
In a discussion at the 2016 CFS,™ Michael Birrer, MD, PhD, director of Medical Gynecologic Oncology at Massachusetts General Hospital, said he anticipates that the FDA will approve niraparib and rucaparib in ovarian cancer in the next 6 months to a year.
The focus now, according to Birrer, is on optimizing the use of these treatments. “We need to find the best patient population to treat and we need to define whether we use these drugs in maintenance treatment, or early or late [in sequencing].” - See more at: http://www.targetedonc.com/conference/cfs-2016/parp-inhibitors-advance-in-ovarian-cancer#sthash.FQHTlMVQ.dpuf
With
olaparib approved and niraparib and rucaparib advancing through
clinical development, PARP inhibition is becoming a valuable option in
the ovarian cancer armamentarium.
In a discussion at the 2016 CFS,™ Michael Birrer, MD, PhD, director of Medical Gynecologic Oncology at Massachusetts General Hospital, said he anticipates that the FDA will approve niraparib and rucaparib in ovarian cancer in the next 6 months to a year.
The focus now, according to Birrer, is on optimizing the use of these treatments. “We need to find the best patient population to treat and we need to define whether we use these drugs in maintenance treatment, or early or late [in sequencing].” - See more at: http://www.targetedonc.com/conference/cfs-2016/parp-inhibitors-advance-in-ovarian-cancer#sthash.FQHTlMVQ.dpuf
In a discussion at the 2016 CFS,™ Michael Birrer, MD, PhD, director of Medical Gynecologic Oncology at Massachusetts General Hospital, said he anticipates that the FDA will approve niraparib and rucaparib in ovarian cancer in the next 6 months to a year.
The focus now, according to Birrer, is on optimizing the use of these treatments. “We need to find the best patient population to treat and we need to define whether we use these drugs in maintenance treatment, or early or late [in sequencing].” - See more at: http://www.targetedonc.com/conference/cfs-2016/parp-inhibitors-advance-in-ovarian-cancer#sthash.FQHTlMVQ.dpuf
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.